Cidara Therapeutics (CDTX)
(Real Time Quote from BATS)
$12.95 USD
-0.14 (-1.07%)
Updated May 15, 2024 11:08 AM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Cidara Therapeutics, Inc. [CDTX]
Reports for Purchase
Showing records 141 - 144 ( 144 total )
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE: 2015 Wedbush PacGrow Healthcare Conference Day 2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
CD101 Enters the Clinic, Quick Data Readout Expected, Reiterate Outperform
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1:EPS; CD101 Granted Qualified Infectious Disease Product (QIDP) With Fast Track Status
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Cidara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $22 Price Target: Better Living through New Antifungals
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D